why choose us

First received: August 25, 2022

Clinical Trial: Intravesical BCG vs GEMDOCE in NMIBC

Study Status: Completed

Recruit Status: RECRUITING

Condition: Non-muscle-invasive Bladder Cancer

Study Type: INTERVENTIONAL


Official Title: A Randomized Phase III Trial of Intravesical BCG veRsus Intravesical Docetaxel and GEmcitabine Treatment in BCG Naïve High Grade Non-Muscle Invasive Bladder Cancer (BRIDGE)

Brief Summary: The study hypothesis is that BCG naïve non-muscle invasive bladder cancer (NMIBC) patients treated with intravesical Gemcitabine + Docetaxel (GEMDOCE) will result in a non-inferior event-free survival (EFS) compared to standard treatment with intravesical BCG.The purpose of this study is to test whether Gemcitabine + Docetaxel is a better or worse treatment than the usual BCG therapy approach.The primary objective of this study is to determine the event free survival (EFS) of BCG-naïve high grade non-muscle…

Read more